KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Liabilities (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Total Liabilities for 11 consecutive years, with $343.4 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 10.8% to $343.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $343.4 million through Dec 2025, up 10.8% year-over-year, with the annual reading at $343.4 million for FY2025, 10.8% up from the prior year.
  • Total Liabilities hit $343.4 million in Q4 2025 for CRISPR Therapeutics AG, up from $329.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $399.4 million in Q3 2022 to a low of $152.4 million in Q1 2021.
  • Historically, Total Liabilities has averaged $337.8 million across 5 years, with a median of $349.6 million in 2021.
  • Biggest five-year swings in Total Liabilities: skyrocketed 137.03% in 2022 and later decreased 11.86% in 2024.
  • Year by year, Total Liabilities stood at $352.4 million in 2021, then increased by 4.3% to $367.6 million in 2022, then dropped by 5.66% to $346.8 million in 2023, then decreased by 10.62% to $310.0 million in 2024, then increased by 10.8% to $343.4 million in 2025.
  • Business Quant data shows Total Liabilities for CRSP at $343.4 million in Q4 2025, $329.3 million in Q3 2025, and $318.6 million in Q2 2025.